Evidence map›Paper›PMID 42486969›Full record

ArticleNature biotechnology2026

Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells.

Adi Nagler, Amit Sud, Jack Y Ghannam, Lucas Pomerance, Camila Robles-Oteiza, Alexander B Afeyan, Jackson A Weir, Andrew J C Russell, Wesley S Lu, McKayla Van Orden and 23 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Adi Nagler *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amit Sud *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6133-0164
Jack Y Ghannam *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0275-9099
Lucas PomeranceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Camila Robles-OteizaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexander B AfeyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0525-7166
Jackson A WeirBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8741-1344
Andrew J C RussellBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5411-2807
Wesley S LuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
McKayla Van OrdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0008-6831-4707
Andrea SonnenholznerLEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0009-0001-6880-7914
Giovanni J MarreroBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1587-3624
Qiyu GongBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Vipin KumarBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2533-9089
Kun HuangMolecular Imaging Core (MIC), Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9100-9638
Chloe TuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Emma LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0005-0560-2849
Bohoon ShimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gabriel R De OliveiraDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0009-0008-6565-7720
MacLean C SellarsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Charles H YoonDepartment of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1231-3840
David A ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6674-0157
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9201-3217
Lars R OlsenDepartment of Bio and Health Informatics, Technical University of Denmark, Copenhagen, Denmark.
Sabina SignorettiHarvard Medical School, Boston, MA, USA.
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4253-943X
David A BraunSection of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4543-5553
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7435-5603
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9106-6141
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9105-5856
Nir HacohenHarvard Medical School, Boston, MA, USA.
Fei ChenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-3348-5054

Funding

Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized LineageK00CA245819 · NCI · DANA-FARBER CANCER INST · PI ROBLES-OTEIZA, CAMILA · 2022 to 2025
$377k
Identifying the Determinants of Immunoediting During Glioblastoma ImmunotherapyF30CA298302 · NCI · HARVARD MEDICAL SCHOOL · PI Jack Ghannam · 2025 to 2026
$85k
Leukemia and Lymphoma Society (Leukemia & Lymphoma Society) 5648-24U.S. Department of Health & Human Services | NIH | Center for Information Technology (Center for Information Technology, National Institutes of Health) CA276865U.S. Department of Health & Human Services | NIH | Center for Information Technology (Center for Information Technology, National Institutes of Health) F30CA298302U.S. Department of Health & Human Services | NIH | Center for Information Technology (Center for Information Technology, National Institutes of Health) K00CA245819Wellcome Trust (Wellcome) 227000/Z/23/Z
6 · The paper itself

Abstract

Improved methods to identify therapeutically relevant tumor neoantigens and their cognate T cells would aid the development of precision medicines for cancer. Here, we developed Slide-GoTags, a droplet-based single-nucleus spatial transcriptomics approach that characterizes neoantigen-specific immunity by integrating targeted transcript genotyping and T cell receptor (TCR) sequencing with single-nucleus RNA sequencing from the same slice of frozen tissue. Application of Slide-GoTags to mouse and human tumors revealed colocalization of clonally expanded, neoantigen-specific T cells with tumor cells expressing their cognate neoantigen. We also identified distinct spatial immune landscapes shaped by anti-PD1 or anti-CTLA4 blockade in mouse colorectal tumors. Across human tumor types, Slide-GoTags detected TCR-neoantigen interactions through spatial proximity and identified an enrichment of interferon-driven immunogenicity niches in immunologically 'hot' tumors compared to 'cold' tumors. These niches harbored three T cell clonotypes that colocalized with genotyped neoantigens, highlighting a spatially organized antitumor immune response. Collectively, Slide-GoTags establishes a framework for in situ mapping of T cell-tumor interactions directly from individual tissue.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.